Join to View Full Profile
300 E 66th StNew York, NY 10065
Phone+1 617-726-2862
Dr. Hellmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008
Certifications & Licensure
NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2023
Clinical Trials
- Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies Start of enrollment: 2019 Mar 08
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Start of enrollment: 2020 Feb 25
Publications & Presentations
PubMed
- 1 citationsHypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, Isabelle Sirois, Arvind Ravi
The Journal of Experimental Medicine. 2025-01-06 - 3 citationsIntratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S Bowman
Journal of Clinical Oncology. 2024-10-01 - 5 citationsAntibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy.Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M Vanderbilt, Pooja Gogia
NPJ Precision Oncology. 2024-07-16
Lectures
- Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.2019 ASCO Annual Meeting - 6/1/2019
- A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021- Memorial Sloan Kettering Awards and AppointmentsAugust 17th, 2020
- The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research ProjectsJuly 7th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
